Back

Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial. - discussion

9 April 2024 (11:05 - 11:09)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Science: devices European Heart Rhythm Association (EHRA) EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Sana Al-Khatib

Duke University Medical Center, Durham (United States of America)

9 More presentations in this session

Presentation thumbnail
Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease
Doctor E. Pisano (Lecce, IT)
Slides Video
Presentation thumbnail
Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease - discussion
Doctor N. Varma (Cleveland, US)
Slides Video
Presentation thumbnail
Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.
Doctor J. Nikorowitsch (Hamburg, DE)
Slides Video
Presentation thumbnail
Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial
Doctor W. McIntyre (Hamilton, CA)
Slides Video
Presentation thumbnail
Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial - discussion
Professor T. Potpara (Belgrade, RS)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Science: devices
Video

The Event

Event poster

EHRA 2024

9 April 2024 11:05 CET
You may be interested in
thumbnail
Congress Presentation
Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.
thumbnail
Congress Presentation
Oral anticoagulation in subclinical atrial fibrillation: pro
thumbnail
Congress Session
Device-detected atrial fibrillation: a new frontier for anticoagulation?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources